-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

968 Favourable Outcomes in Newly Diagnosed Paediatric AML with Gemtuzumab Ozogamicin and Risk-Stratified Therapy: Results from the International Phase III Myechild 01 Trial

Program: Oral and Poster Abstracts
Type: Oral
Session: 617. Acute Myeloid Leukemias: Commercially Available Therapies: Optimizing Regimens in Children/Young Adults and Around the World
Hematology Disease Topics & Pathways:
Research, Clinical trials, Acute Myeloid Malignancies, AML, Clinical Research, Pediatric, Diseases, Myeloid Malignancies, Study Population, Human
Monday, December 9, 2024: 4:45 PM

Brenda Gibson, MD1*, Andre Baruchel, MD2*, Andrew Moore, MBBS, PhD, FRACP3*, Shanna Maycock, MSc4*, Owen Smith, MD5*, Geoff Shenton6*, Jean-Pierre Bourquin, MD, PhD7, Yves Bertrand, MD8*, Nicholas Heaney1*, Anna Lawson, BSc9*, Persis Jal Amrolia10*, Gerard Michel, MD, PhD11*, Jean-Hugues Dalle, MD, PHD12, Marc Ansari, MD, PhD13, Hélène Lapillonne, MD, PhD14*, Richard Dillon, MA15, Jelena Jovanovic, PhD16*, Siobhan Cross, MD17*, Paul Virgo18*, Lucy Wheeler19*, Christophe Roumier, PharmD20*, Nicolas Duployez, PharmD, PhD21*, Christine Harrison, PhD, FRCPath22*, Claire Schwab, PhD22*, Wendy Cuccuini, MD, PhD23*, Marina Lafage-Pochitaloff, MD, PhD24*, Claude Preudhomme, PharmD, PhD25*, Paresh Vyas, FMedSci, DPhil, FRCPath26*, Pierre Hirsch, MD, PhD27*, Gareth Veal, PhD22*, David Gillis, MBBS, FRACP, FRCPA28*, Pam Kearns, MBChB, PhD, FRCPC9*, Guy Leverger, MD, PhD29*, Phil Ancliff30*, Aimee Jackson, BSc MSc31* and Arnaud Petit, MD, PhD32*

1Royal Hospital for Children, Glasgow, Glasgow, United Kingdom
2Hôpital Universitaire Robert Debré (APHP and Université Paris Cité), Paris, France
3Child Health Research Centre, The University of Queensland, South Brisbane, QLD, Australia
4Cancer Research UK Clinical Trials Unit, University of Birmingham, Edgbaston, United Kingdom
5Children's Health Ireland, Dublin, Ireland
6Great North Children’s Hospital, Newcastle, United Kingdom
7Department of Pediatric Oncology, University Children's Hospital Zurich, Zurich, Switzerland
8Pediatric Hematology, Institut d'Hématologie et Oncologie Pédiatrique, Lyon, France
9Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom
10Bone Marrow Transplant Department, Great Ormond Street Hospital, London, United Kingdom
11CHU de Marseille Hôpital de la Timone Enfants, Marseille, France
12Department of Pediatric Hematology and Immunology, Robert-Debré Academic Hospital ,, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France
13Department of Pediatrics, Onco-Hematology Unit,, Geneva University Hospital, Geneva, Switzerland
14Laboratory of Hematology and Flow cytometry, Trousseau Hospital, Paris, France
15Guy's and St. Thomas' NHS Foundation Trust, London, ENG, United Kingdom
16King’s College London, London, United Kingdom
17Christchurch Hospital, Christchurch, NZL
18Southmead Hospital, Bristol, GBR
19Southmead Hospital, North Bristol NHS Trust, Bristol, United Kingdom
20ONCOLILLE - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Centre Hospitalier Universitaire (CHU) de Lille, Lille, France
21Laboratory of Hematology-Molecular Biology, Centre Hospitalier Universitaire (CHU) de Lille, Lille, France
22Newcastle University, Newcastle, United Kingdom
23Saint Louis Hospital, Paris, France
24CHU Timone Enfants, Marseille, France
25Laboratory of Hematology-Molecular Biology, CHU Lille, Lille, France
26Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
27Hematology Laboratory, Saint Antoine University Hospital, AP-HP, Paris, France
28Royal Brisbane and Women's Hospital, Brisbane, Australia
29Pediatric Hematology Oncology Immunology Department, Hôpital Trousseau, Paris, France
30Department of Haematology, Great Ormond Street Hospital for Children, London, United Kingdom
31Cancer Research UK Trials Unit, University of Birmingham, Birmingham, United Kingdom
32Hôpital Armand Trousseau, APHP, PARIS, Île-de-France, France

Introduction

Adding one dose of 3mg/m2 of Gemtuzumab ozogamicin (GO), an anti CD33 antibody drug conjugate, showed an event-free survival (EFS) benefit in children with acute myeloid leukaemia (AML) in the AAML0531 trial (Gamis et al, JCO, 2014) whilst the adult ALFA-0701 trial reported a survival benefit of 3 fractionated doses with standard induction (Castaigne et al, Lancet, 2012). MyeChild 01, an international trial (UK, France, Australia, New Zealand, Ireland, Switzerland) for paediatric AML, high risk myelodysplastic syndrome (MDS > 10% blasts) or isolated myeloid sarcoma (IMS), embedded a GO dose finding study which established the safety of combining up to 3 doses of 3mg/m2 with intensive induction chemotherapy. 515 patients were randomised to 1 vs 3 doses of GO during course 1 (given on day 4 or days 4, 7, and 10 respectively), from Jan-2019 to Jun-2022. Due to regulatory commitments comparative results by randomisation are not available at the time of writing, but these data will be presented at the ASH annual meeting. Overall results are presented here.

Methods

Randomisation of GO doses was stratified by age; diagnosis (AML, MDS, IMS); disease type (de novo, secondary); white cell count (WCC) (<100, ≥100x109/L). Statistical analyses are by intention to treat with a primary outcome of EFS.

All patients were allocated mitoxantrone and cytarabine (MA) with GO in course 1 and thereafter stratified by cyto/molecular genetics, remission status after course 1 and measurable residual disease (MRD). Patients with resistant disease post course 1 or poor risk (PR) cyto/molecular genetics were stratified high risk (HR) and received fludarabine, cytarabine and idarubicin (FLA-Ida) for course 2; all other patients received a second course of MA. Data is available on 472 patients; 142 received FLA-Ida and 330 MA. HR patients proceeded to allogeneic stem cell transplantation (HSCT). Non-HR patients were subsequently allocated treatment based on their cyto/molecular genetics and MRD response.

Results

Patient characteristics were: males 55%; median age 10yr; median WCC 14 x109/L; AML 96%, MDS 2.5%, isolated MS 1.9%; de novo 98%; CNS2 16%, CNS3 9%; non CNS extramedullary disease 16%.

Of 515 patients randomised to 1 vs 3 doses, all but 16 received GO (6 ineligible, 5 prior toxicity, 5 other). 179 patients (35%) had a confirmed HSCT. Median follow-up is 3 years.

The overall 2 yr EFS is 70% (95% CI: 66-74%) and overall survival (OS) 88% (85-91%). 94% achieved complete remission (CR) or CR with incomplete count recovery (CRi) post course 1 or 2; 6% failed to achieve CR/CRi (resistant disease 2.5%, non-evaluable 1%, unknown response 2.3%). 127 of 485 patients who achieved CR/CRi have relapsed giving a 2 yr cumulative incidence of relapse (CIR) of 25% (21-29%). Overall, there were 79 deaths but only 11 (2%) in first remission. 63 deaths were disease-related, 12 transplant-related, 3 off-trial treatment related and 1 other non-cancer.

A cyto/molecular risk group was available for 485 patients: 192 GR (40%), 162 IR (33%) and 131 PR (27%). GR patients had a CR/CRi of 100%, 2 yr EFS 81% (76-87%), CIR 18% (13-24%) and OS 96% (93-99%); IR patients had a CR/CRi of 97.5%, 2 yr EFS 64% (57-72%), CIR 33% (26-41%) and OS 87% (82-93%); PR patients had a CR/CRi of 93.9%, 2 yr EFS 68%(61-77%), CIR 24%(16-32%) and OS 78% (71- 85%).

Time to count recovery was defined as time from day 1 of a course to date of neutrophils >0.75 x109/L and platelets >75 x 109/L. Median count recovery was 41days post course 1, 44 days post course 2 MA and 45 days post course 2 FLA-Ida.

59% of patients had at least one grade ≥3 adverse event or any grade serious adverse event, evaluated from the start of treatment until 30 days after end of induction. Most events were consistent with AML chemotherapy. Only 9 patients (1.7%) had grade ≥3 hyperbilirubinemia and 2 patients confirmed veno-occlusive disease (VOD) in induction.

Conclusion

At least one dose of GO in combination with mitoxantrone and cytarabine in induction followed by risk-adapted therapy has produced excellent results. Despite intensive treatment the death in first remission rate is remarkably low at 2% and VOD was rare. Although this abstract reports only pooled data, outcomes for the 1 vs 3 dose GO randomisation will be presented at the ASH annual meeting.

Disclosures: Gibson: Vertex: Membership on an entity's Board of Directors or advisory committees; GSK: Current holder of stock options in a privately-held company; Novartis: Current holder of stock options in a privately-held company. Baruchel: Servier: Other: Symposia and Travels; Wugen: Other: Adboard; Astra Zeneca: Other: Adboard; Novartis: Other: Symposia and Travels. Amrolia: Autolus PLC: Research Funding. Dalle: Vertex: Consultancy, Honoraria; Symbiopharm: Consultancy, Honoraria; Orchard: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Pierre Fabre Médicaments: Consultancy, Honoraria, Other: travels; Pfizer: Consultancy, Honoraria; Teva: Current equity holder in private company. Ansari: NovoNordisk: Other: traveling grant; Jazz Pharmaceutical: Other: traveling grant and presentation inside the company on HSCT. Dillon: Abbvie, Amgen: Other: Research support (paid to institution); Jazz: Other: Consultancy and educational events (paid to institution); Abbvie, Astellas, Pfizer: Consultancy, Other: Educational events. Preudhomme: astellas: Honoraria; abbvie: Other: travel cost and ash registration; jazz: Honoraria; servier: Honoraria. Vyas: Abbvie, Servier, Rigel, Syndax, AstraZeneca, Debiopharm, Charm Therapeutics: Consultancy; Yellowstone Biosciences: Current equity holder in private company, Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Research Funding; Auron Therapeutics: Membership on an entity's Board of Directors or advisory committees. Kearns: Pfizer: Research Funding. Ancliff: GSK: Current holder of stock options in a privately-held company.

OffLabel Disclosure: Mitoxantrone and gemtuzumab ozogamicin are both licensed for use in this condition in the adult population but their use is off label for the paediatric population.

*signifies non-member of ASH